Curalogic announces top line results from Phase III clinical study with the ragweed product

Announcement no. 26/2007                                                        


To the OMX Nordic Exchange	                           Copenhagen, December 21,  
2008                                                                            






Curalogic announces top line results from Phase III clinical study with the     
ragweed product                                                                 

Summary: The result from the Phase III clinical study with the ragweed product  
(RPE 04) shows that the dose tested is not efficacious. Curalogic puts the      
development activities on the ragweed product on hold.                          

Curalogic has completed a Phase III clinical study (RPE 04) with the product for
the treatment of ragweed allergy. The study involved 545 patients in the United 
States, Italy, Hungary and Serbia. The result from the study shows that the     
patients in both the active and placebo groups experienced significant increases
in the allergy symptoms during the ragweed allergy season (p>0.001), which means
that the right patients were included in the study and that the season was      
satisfactory. Patients received between 10 and 24 weeks of treatment with the   
product before the ragweed pollen season. The primary efficacy measure in the   
study was a reduction in allergy symptoms and the result shows that there were  
no difference in the allergy symptoms between the active and placebo group in   
the “ITT population”. The ITT population is all patients enrolled in the study. 

Analysis of the “per protocol population”, USA versus European sites and the    
effect of duration of the pre-seasonal treatment gives the same conclusion. The 
per protocol population is all the patients that have completed the study as    
defined in the protocol. An analysis of the plasma concentration of ragweed     
specific immunoglobulins in the blood shows a significant increase in the active
group (p>0.001), which is in line with results from earlier clinical studies    
with the ragweed product. The safety profile of the ragweed product is in line  
with the earlier clinical studies.                                              

The overall conclusion of the RPE 04 study is that the tested dose is not       
efficacious and this means that Curalogic will not be able to file a            
registration application for the ragweed product in Europe in 2008 as planned.  

Peter Moldt, CEO of Curalogic, said: “Technically the study is well conducted,  
but unfortunately we must conclude that the study clearly shows that the tested 
dose is not efficacious. Based on the results from the RPE 04 study we will put 
the development activities with the ragweed product on hold and we will conduct 
a detailed analysis of study results with our clinical advisors. “              

A through strategic review will be conducted during which time Curalogic will   
continue the work on the grass and house dust mite projects. Curalogic expects  
to give an update by the end of January 2008. Curalogic's cash and cash         
equivalents amounted to DKK 393.2 millions as of September 30, 2007 (USD 78     
million).                                                                       

Design of the Phase III clinical study                                          
RPE 04 was a double-blinded, randomized placebo-controlled study which was      
conducted in 2007 ragweed pollen season. The study objective was to evaluate the
efficacy and safety of a daily dose of orally administered ragweed pollen       
extract to patients suffering from ragweed allergy.                             


Yours sincerely                                                                 

Curalogic A/S                                                                   


For additional information, please contact:                                     
Peter Moldt, President and CEO	Phone +45 99 99 24 00, mobile +45 26 25 04 22    
Helle Busck Fensvig, EVP and CFO 	Phone +45 99 99 24 00, mobile +45 20 70 55 37 



About Curalogic                                                                 
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic        
Exchange (CUR.CO) as a small cap + company. Curalogic develops innovative       
products for the treatment of allergy using a patented formulation technology.  
The drugs combine the efficacy of immunotherapy with the patient friendliness of
antihistamines and have the potential to become the preferred type of allergy   
treatment among patients. Curalogic has a broad and mature pipeline of products 
for the treatment of ragweed allergy and grass allergy in Phase III and products
for the treatment of house dust mite allergy and cat allergy in Phase II.       





































This announcement contains forward-looking statements regarding the Company's   
future financial development and performance and other statements which are not 
historical facts. Such statements are made on the basis of assumptions and      
expectations which, to the best of the Company's knowledge and belief, are      
reasonable, at this time, but may prove to be erroneous in the future.